The article discusses a novel implantable wafer system called CANDI that delivers immunostimulatory small molecules to reprogram immunosuppressive myeloid cells in glioblastoma, leading to long-term survival and prevention of tumor recurrence in mouse models, with promising implications for human treatment.
Researchers have identified a potential strategy to reverse therapy resistance in prostate cancer by targeting myeloid chemotaxis. Myeloid cells play a crucial role in tumor progression and therapy resistance, and the study found that inhibiting the chemotaxis of these cells can enhance the effectiveness of existing therapies. The findings provide a promising avenue for developing targeted treatments for prostate cancer patients who have developed resistance to current therapies.
A new study supported by the National Institutes of Health has found that a subset of white blood cells known as myeloid cells can harbor HIV in people who have been virally suppressed for years on antiretroviral therapy. The study suggests that myeloid cells contribute to a long-lived HIV reservoir, making these cells an important but overlooked target in efforts to eradicate HIV. The researchers note that larger studies with more diverse participant pools will be essential to accurately estimate the proportion of people who have latent HIV in myeloid cells.